Gene replacement strategies for Duchenne muscular dystrophy (DMD) employing the adeno-associated virus (AAV) face the challenge imposed by the limited packaging capacity of AAV, only allowing the accommodation of a short version of dystrophin (μDys) that is still far removed from correcting human disease. Here, DMD is linked to Duchenne muscular dystrophy.